{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T23:06:18Z","timestamp":1762988778422,"version":"3.45.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Isr J Health Policy Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Compassionate use programs allow patients with life-threating and serious conditions to access investigational therapies when standard treatments are inadequate. This study aims to analyze the trends and outcomes of the compassionate use of medicinal products in Israel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data from the Israeli Ministry of Health\u2019s compassionate use database (2020\u20132024) were anonymized and analyzed. Duplicates were removed, and a pivot table was used to assess factors such as active ingredients, indications, treatment counts, and patient demographics. Results were presented as counts and percentages, with treatments over 0.5% of the total classified as common. Statistical analyses included Student\u2019s t-test and chi-squared test for subgroup differences (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05 significant). Commonly used medicinal products were cross-referenced with the MOH drug database for registration and reimbursement status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 3,284 compassionate treatments were administered, employing 596 distinct medicinal products to address 1,361 conditions in 2020\u20132024. Temporal analysis identified a peak in 2020, which accounted for 24% of total treatments, followed by a decrease thereafter. Patient age stratification indicated that those aged 65 to 80 received the highest treatment proportion (26%), while the 45 to 65 age group accounted for 19%. Treatments were mainly concentrated in large central hospitals (77%) and the central district (49%), with the southern district showing the least usage. The authorization process was primarily for the continuation of study drug in 63% of cases. Additionally, Belantamab mafodotin and Trametinib were the most frequently utilized medicinal products, accounting for 9% and 8.6% of treatments, respectively. Disease category analysis revealed that relapsed refractory multiple myeloma, central nervous system tumors, and inflammatory bowel disease were among the top conditions treated, varying by age group. Notably, 60% of the most common technologies (13 out of 22) were subsequently included into the national health basket, typically following an extended period of compassionate use that exceeded two years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study suggests that Israel\u2019s compassionate use programs have accelerated early access to novel therapies for complex conditions and provided a bridge to the inclusion of novel medicinal products in the national health basket. Nonetheless, the study identifies a concerning downward trend in utilization alongside potential access disparities, thereby underscoring the necessity for further targeted investigations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13584-025-00730-3","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T23:02:30Z","timestamp":1762988550000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Trends in compassionate use of medicinal products: Israel 2020\u20132024"],"prefix":"10.1186","volume":"14","author":[{"given":"Eyal","family":"Schwartzberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Marom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Finkel-Pekarsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Segev","family":"Shani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam Cohen","family":"Kandli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Aboukaoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"730_CR1","unstructured":"Pharmacists. Ordinance new version 5741\u2009\u2013\u20091981 Hebrew. Accessed; April 2025. https:\/\/www.gov.il\/he\/pages\/rokhut23."},{"key":"730_CR2","unstructured":"Pharmacists Regulations. Medicinal Products) 5746\u2009\u2013\u20091986 Hebrew. Accessed; April 2025. https:\/\/www.nevo.co.il\/law_html\/law00\/4850.htm."},{"key":"730_CR3","unstructured":"Director General circular 30\/. 2006, Guidelines and Clarifications for Conditions of Administrative Approval for Compassionate Care Treatment, Hebrew Director https:\/\/www.gov.il\/BlobFolder\/policy\/mk30-006\/he\/files_circulars_mk_mk30_2006.pdf. Accessed April 2025."},{"key":"730_CR4","unstructured":"Director\u2019s Approval According to the Pharmacists Regulations. (Medicinal Products) of 1986, Hebrew. https:\/\/www.gov.il\/BlobFolder\/legalinfo\/rokhut31\/he\/files_legislation_Rokhut_Rokhut31.pdf. Accessed April 2025."},{"key":"730_CR5","unstructured":"Procedure 14 of the Pharmaceutical Division. Ministry of Health - Procedure for Clinical Trials in Human Beings, 2020 Version, Hebrew. https:\/\/www.gov.il\/he\/pages\/protocol-of-medical-research-involving-human-subjects"},{"key":"730_CR6","unstructured":"The National Cancer Institute for Compassionate Use. https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/compassionate-use. Accessed, April 2025."},{"key":"730_CR7","unstructured":"The US Food and Drug Administration expanded access. https:\/\/www.fda.gov\/news-events\/public-health-focus\/expanded-access. Accessed, April 2025."},{"key":"730_CR8","unstructured":"Committee for Medicinal Products for Human Use (CHMP). https:\/\/www.ema.europa.eu\/en\/committees\/committee-medicinal-products-human-use-chmp. Accessed, April 2025."},{"key":"730_CR9","unstructured":"Regulation (EC). No 726\/2004 of the European Parliament and of the Council of 31 March 2004 laying down community procedures for the authorisation and supervision of medicinal products for human and veterinary use and Establishing a European medicines agency (Text with EEA relevance). Accessed; April 2025. http:\/\/data.europa.eu\/eli\/reg\/2004\/726\/oj."},{"key":"730_CR10","unstructured":"EMA Compassionate Use. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compassionate-use. Accessed, April 2025."},{"key":"730_CR11","unstructured":"Israeli drug database maintained by the MOH. https:\/\/israeldrugs.health.gov.il\/#!\/byDrug. Accessed April 2025."},{"key":"730_CR12","doi-asserted-by":"publisher","first-page":"102591","DOI":"10.1016\/j.jhealeco.2022.102591","volume":"82","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Gaule P. What drives innovation? Lessons from COVID-19 R&D. J Health Econ. 2022;82:102591. https:\/\/doi.org\/10.1016\/j.jhealeco.2022.102591.","journal-title":"J Health Econ"},{"key":"730_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-020-00358-5","author":"N Ayati","year":"2020","unstructured":"Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the pharmaceutical sector. DARU J Pharm Sci. 2020. https:\/\/doi.org\/10.1007\/s40199-020-00358-5.","journal-title":"DARU J Pharm Sci"},{"issue":"4","key":"730_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/jof6040239","volume":"6","author":"KJ Shaw","year":"2020","unstructured":"Shaw KJ, Ibrahim AS, Fosmanogepix. A review of the First-in-Class broad spectrum agent for the treatment of invasive fungal infections. J Fungi (Basel). 2020;6(4):239. https:\/\/doi.org\/10.3390\/jof6040239.","journal-title":"J Fungi (Basel)"},{"key":"730_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1504803","author":"B Siegel","year":"2025","unstructured":"Siegel B, Patil P, Prakash A, Klawinski D, Hwang E. Targeted therapy in pediatric central nervous system tumors: a review from the National Pediatric Cancer Foundation. Front Oncol. 2025. https:\/\/doi.org\/10.3389\/fonc.2025.1504803.","journal-title":"Front Oncol"},{"key":"730_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01054-1","author":"M Bent","year":"2023","unstructured":"Bent M, Geurts M, French P, Smits M, Capper D, Bromberg J, Chang S. Primary brain tumours in adults. Lancet. 2023. https:\/\/doi.org\/10.1016\/S0140-6736(23)01054-1.","journal-title":"Lancet"},{"key":"730_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030712","author":"A Leibetseder","year":"2022","unstructured":"Leibetseder A, Preusser M, Berghoff A. New approaches with precision medicine in adult brain tumors. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030712.","journal-title":"Cancers (Basel)"},{"key":"730_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205154","author":"K Podar","year":"2021","unstructured":"Podar K, Leleu X. Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13205154.","journal-title":"Cancers (Basel)"},{"key":"730_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00695-5","author":"S Kumar","year":"2022","unstructured":"Kumar S, Baizer L, Callander N, Giralt S, Hillengass J, Freidlin B, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI multiple myeloma steering committee. Blood Cancer J. 2022. https:\/\/doi.org\/10.1038\/s41408-022-00695-5.","journal-title":"Blood Cancer J"},{"issue":"21","key":"730_CR20","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1158\/1078-0432.ccr-22-0618","volume":"28","author":"A Baines","year":"2022","unstructured":"Baines A, et al. Fda approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma. Clin Cancer Res. 2022;28(21):4629\u201333. https:\/\/doi.org\/10.1158\/1078-0432.ccr-22-0618.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"730_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bjh.18479","volume":"200","author":"T Shragai","year":"2022","unstructured":"Shragai T, et al. Real-world experience with belantamab mafodotin therapy for relapsed\/refractory multiple myeloma: a multicentre retrospective study. Br J Haematol. 2022;200(1):45\u201353. https:\/\/doi.org\/10.1111\/bjh.18479.","journal-title":"Br J Haematol"},{"key":"730_CR22","doi-asserted-by":"publisher","unstructured":"Rubia J et al. Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma included in the compassionate use or the expanded access program. experience with a spanish cohort. Blood, vol. 140, no. Supplement 1, 2022, pp. 4315\u20134317. https:\/\/doi.org\/10.1182\/blood-2022-158538","DOI":"10.1182\/blood-2022-158538"},{"key":"730_CR23","doi-asserted-by":"publisher","unstructured":"Alegre Adri\u00e1n, Compassionate use of belantamab mafodotin for treatment of patients with relapsed\/refractory multiple myeloma heavily treated. spanish experience. Blood 2021;138:3775\u20133775. https:\/\/doi.org\/10.1182\/blood-2021-151267","DOI":"10.1182\/blood-2021-151267"},{"key":"730_CR24","doi-asserted-by":"publisher","unstructured":"Rubia, Javier, Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: results of the compassionate use or the expanded access program in spain. Cancers 2023;15(1):2964. https:\/\/doi.org\/10.3390\/cancers15112964","DOI":"10.3390\/cancers15112964"}],"container-title":["Israel Journal of Health Policy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-025-00730-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13584-025-00730-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13584-025-00730-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T23:02:31Z","timestamp":1762988551000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijhpr.biomedcentral.com\/articles\/10.1186\/s13584-025-00730-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1186\/s13584-025-00730-3","relation":{},"ISSN":["2045-4015"],"issn-type":[{"type":"electronic","value":"2045-4015"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.The study is a retrospective database analysis, not including individual details. Consent to Participate declaration not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not applicable.\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}